Methods to quantify cell signaling and gpcr receptor ligand bias: Characterization of drugs that target the endocannabinoid receptors in Huntington’s disease

Producción científica: Capítulo en Libro/Reporte/Acta de conferenciaCapítulo

7 Citas (Scopus)

Resumen

G protein-coupled receptors (GPCRs) interact with multiple intracellular effector proteins such that different ligands may preferentially activate one signal pathway over others, a phenomenon known as signaling bias. Signaling bias can be quantified to optimize drug selection for preclinical research. Here, we describe moderate-throughput methods to quantify signaling bias of known and novel compounds. In the example provided, we describe a method to define cannabinoid-signaling bias in a cell culture model of Huntington’s disease (HD). Decreasing type 1 cannabinoid receptor (CB 1 ) levels is correlated with chorea and cognitive deficits in HD. There is evidence that elevating CB 1 levels and/or signaling may be beneficial for HD patients while decreasing CB 1 levels and/or signaling may be detrimental. Recent studies have found that Gα i/o -biased CB 1 agonists activate extracellular signal-regulated kinase (ERK), increase CB 1 protein levels, and improve viability of cells expressing mutant huntingtin. In contrast, CB 1 agonists that are β-arrestin1-biased were found to reduce CB 1 protein levels and cell viability. Measuring agonist bias of known and novel CB 1 agonists will provide important data that predict CB 1 -specific agonists that might be beneficial in animal models of HD and, following animal testing, in HD patients. This method can also be applied to study signaling bias for other GPCRs.

Idioma originalEnglish
Título de la publicación alojadaMethods in Molecular Biology
EditorialHumana Press Inc.
Páginas549-571
Número de páginas23
DOI
EstadoPublished - 2018

Serie de la publicación

NombreMethods in Molecular Biology
Volumen1780
ISSN (versión impresa)1064-3745

Nota bibliográfica

Funding Information:
This work was supported by a Bridge Funding Grant from Dalhousie University to EMD-W. A.M.B. was supported by studentships from Dalhousie University and King Abdulaziz University, Jeddah, Saudi Arabia. R.B.L. was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research.

Publisher Copyright:
© Springer Science+Business Media, LLC, part of Springer Nature 2018.

ASJC Scopus Subject Areas

  • Molecular Biology
  • Genetics

Huella

Profundice en los temas de investigación de 'Methods to quantify cell signaling and gpcr receptor ligand bias: Characterization of drugs that target the endocannabinoid receptors in Huntington’s disease'. En conjunto forman una huella única.

Citar esto